Clinical trial
Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent…
NCT00185861 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00185861 |
|---|---|
| Title | Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma |
| Official title | Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma |
| Lead sponsor | Stanford University, Other |
| Collaborators | Cephalon Industry CTI BioPharma |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Arsenic Trioxide, Stereotactic radiosurgery |
| Enrollment | 12 |
| Start date | Dec 1, 2003 |
| Primary completion | Jan 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Sep 16, 2005 |
| Last update posted | Apr 9, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: